title: The Adjunctive Use of Anti-vascular Endothelial Growth Factor Agents in the Management of Iris Neovascularisation in Malaysia.
abstract: This retrospective study investigated the role of antivascular endothelial growth factor agents (VEGF), ranibizumab, bevacizumab and pegaptanib sodium in patients with iris neovascularisation (INV), in which 9 eyes received intraocular injections for various ischaemic ocular conditions. Ocular sequelae included recurrence of rubeosis (n=2) and hyphaema (n=2). Systemic complication included one case of cerebrovascular accident. INV regressed in all cases from day one. INV recurrence occurred in 2 cases. The mean intraocular pressure of the study eyes decreased from 25.3 mmHg to 18.3 mmHg at one month. Five eyes are medication free. Visual acuity improved in 5 eyes. Four eyes achieved a Snellen visual acuity of 6/24 or better. We conclude that the use of intraocular anti-VEGF agents are safe and effective for inducing the regression of INV. Patients with multiple systemic risk factors should be counseled on stroke risk.
authors.affiliation: Universiti Kebangsaan Malaysia, Ophthalmology, Department of Ophthalmology, Hospital UKM, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia. maelynnbdr@gmail.com.
authors.forename: M L C
authors.initials: ML
authors.lastname: Bastion
authors.forename: K Y
authors.initials: KY
authors.lastname: Then
authors.forename: H A
authors.initials: HA
authors.lastname: Faridah
authors.forename: M
authors.initials: M
authors.lastname: Mushawiahti
authors.forename: O
authors.initials: O
authors.lastname: Othmaliza
authors.forename: H S
authors.initials: HS
authors.lastname: Wong
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007498:Iris; D008296:Malaysia; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A